alexa
Reach Us +44-7482878454
Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort | OMICS International | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort

Jean-Luc Meynard1*, Laurence Morand-Joubert2, Geneviève Chêne3, Roland Landman4, Alexandrina Pinta5, Sandrine Kraemer5, Martine Obadia6 and Pierre-Marie Girard1

1Service des Maladies Infectieuses, Hôpital Saint-Antoine, Paris, France

2Laboratoire de Virologie, AP-HP, CHU Saint-Antoine, INSERM U943, Paris, France

3Unité INSERM 593, Bordeaux, France

4IMEA, Paris, France

5Roche, Neuilly-sur-Seine, France

6Hôpital Purpan, Toulouse, France

*Corresponding Author:
Dr. Jean-Luc Meynard
Hôpital Saint-Antoine
Service de Maladies Infectieuses et Tropicales
184 rue du Faubourg Saint-Antoine, 75012 Paris, France
Tél: 33 (0)1 49.28.28.66
Fax: 33 (0)1 49.28.21.49
E-mail: [email protected]

Received Date: November 15, 2010; Accepted Date: January 05, 2011; Published Date: January 06, 2011

Citation: Meynard JL, Morand-Joubert L, Chêne G, Landman R, Pinta A, et al. (2011) Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort. J AIDS Clinic Res 2:114. doi:10.4172/2155-6113.1000114

Copyright: © 2011 Meynard JL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The objective of this study was to describe, in real-life settings, the patients treated by the HIV fusion inhibitor enfuvirtide and to evaluate efficacy and safety of this new antiretroviral drug in comparison with the results of the pivotal studies TORO 1 and TORO 2.

Adult HIV-1-infected patients, treated for the first time with enfuvirtide since less than 2 months, were eligible for the study. From September 2004 to May 2006, 364 patients (male, 81%) with a mean (SD) age of 45 (9) years and at CDC stage C for 52% of them were included and followed for 2 years. The median duration of antiretroviral treatment was 10 years with a median number of 11 drugs. Median HIV viral load was 4.7 log 10 copies/mL and median CD4 cell count was 155 cells/mm 3 (respectively, 5.2 log 10 copies/mL and 89 cells/mm 3 in TORO studies). Compared to the TORO studies, the proportion of patients on enfuvirtide treatment with HIV RNA < 400 copies/mL in ZOOM study was higher (61 vs. 34% at 1 year; 77 vs. 48% at 2 years). The immunologic benefit was approximately the same at 2 years (+173 cells/mm 3 in ZOOM vs. +166 cells/mm 3 in TORO studies). Bacterial pneumonia was reported for 5 patients (0.81 case for 100 patient-years).

In conclusion, in real-life settings, the results of the ZOOM study at 2 years confirmed the virologic and immunologic benefits and the favorable safety of enfuvirtide reported in the TORO pivotal trials.

Recommended Conferences
Share This Page
Top